PAPILLOMAVIRUS ANIMAL MODEL/THERAPY EVALUATION

乳头瘤病毒动物模型/治疗评估

• 批准号: 2297266
• 负责人: JOHN W KERGDER
• 金额: $ 25.08万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-03-01 至 1993-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2297266
• 关键词: PAPILLOMAVIRUS; ANIMAL; MODEL; THERAPY; EVALUATION

Papillomavirus infections are responsible for several clinically important diseases. The annual worldwide incidence of cervical carcinoma is about 450,000 cases and prior infection with a human papillomavirus (HPV) has been strongly implicated as the most consistently identified cofactor in the etiology of the neoplasm. In addition, HPV is the causative agent of condyloma acuminatum, a sexually transmitted infection which is currently spreading more rapidly than genital herpes. The incidence of this disease increased 500% between 1966 and 1981 (MMWR 32:306- 308, 1983). Exuberant growths of condyloma are often seen in immunosuppressed patients; those whose immune systems are suppressed by temporary conditions such as pregnancy as well as AIDS patients and other seriously immune deficient individuals. HPV is also the cause of recurrent respiratory papillomatosis (RRP), a rare (approximately 1500 new cases per year in the U.S.) but devastating infection which afflicts children as well as adults. In addition to supporting clinical trials of promising therapeutic agents, the Antiviral Substances Program (ASP) maintains a variety of animal models of human infections in which experimental therapies can be evaluated prior to clinical trial. Several animal models of papillomavirus infections are available which share many features with human disease. The objectives of this contract are: 1. The use of the Shope papillomavirus rabbit model and the xenograft model of human papillomavirus infection of nude mice for evaluation of experimental antiviral therapies. 2. Basic research on the natural history and pathogenesis of papillomavirus infections that may well suggest successful strategies for controlling infection.

乳头瘤病毒感染负责多种临床 重要疾病。 宫颈年度年度发病率 癌约为450,000例，并事先感染人类 乳头状瘤病毒（HPV）被强烈暗示是最大的 在肿瘤的病因中始终鉴定出辅助因子。 另外，HPV是对照瘤的病因 Acuminatum，一种性传播感染，目前是 比生殖器疱疹更快地传播。 此的发生率 疾病在1966年至1981年之间增加了500％（MMWR 32：306- 308，1983）。 经常在 免疫抑制患者；那些免疫系统是 受到怀孕等临时条件的抑制 艾滋病患者和其他严重免疫缺陷的个体。 HPV也是复发性呼吸乳头状瘤病的原因 （RRP），这是一个罕见的（美国每年约1500例新案件） 但是遭受儿童和成年人的毁灭性感染。 除了支持有希望的治疗的临床试验 代理商，抗病毒药物计划（ASP）维护 人类感染的各种动物模型 可以在临床试验之前评估实验疗法。 有几种乳头瘤病毒感染的动物模型 与人类疾病共享许多特征。 目标的目标 该合同是： 1。使用Shope Papillomavirus Rabbit模型和 裸鼠的人乳头瘤病毒感染的异种移植模型 用于评估实验性抗病毒疗法。 2。关于自然历史和发病机理的基础研究 乳头瘤病毒感染很可能暗示成功 控制感染的策略。